Psoriatic Arthritis Treatment Market – Advanced Therapies for Chronic Inflammatory Joint Disease

0
386

The psoriatic arthritis treatment market is a critical segment of the pharmaceutical industry, providing advanced therapies for patients with psoriatic arthritis, a chronic inflammatory joint disease associated with psoriasis. With rising prevalence of psoriatic arthritis, growing demand for biologic therapies, advancements in treatment options, and increasing awareness of psoriatic arthritis, this market is experiencing robust growth.

The market was valued at USD 5.8 billion in 2024, about USD 6.2 billion in 2025, and is projected to reach roughly USD 12.0 billion by 2035, growing at a CAGR of approximately 6.8%. Growth is driven by the increasing prevalence of psoriatic arthritis, growing demand for biologic therapies, advancements in treatment options, rising awareness of psoriatic arthritis, and healthcare access improvements.

By treatment type, biologics hold the largest share (valued at USD 1,389 million in 2024 and projected to reach USD 3,111 million by 2035), reflecting their increasing acceptance among healthcare providers and effectiveness in managing symptoms. Nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs, and targeted synthetic DMARDs also contribute significantly, each offering specific therapeutic benefits for different patient needs.

By route of administration, oral and topical administrations continue to gain traction among patients due to their convenience and ease of use. Injectable options remain relevant, particularly for those requiring immediate effects and targeted delivery, while intravenous options are utilized for severe cases where swift action is required.

By patient type, adult patients considerably comprise the majority holding within this market segment, driven by the prevalence of psoriatic arthritis among this age group in various regions worldwide. Pediatric patients, although a smaller segment, are increasingly recognized as a crucial demographic as awareness of juvenile psoriatic arthritis rises.

By severity of disease, mild cases often involve non-steroidal anti-inflammatory drugs, while moderate cases typically require advanced therapies to effectively manage symptoms and prevent progression. Severe cases, where patients experience significant joint damage and quality of life impairment, are generally treated with biologics and other targeted therapies.

Regionally, North America is anticipated to dominate the market, maintaining a leading role throughout the forecast period, driven by high healthcare expenditure and prevalence of psoriatic arthritis. Europe is expected to hold a significant share, benefiting from advanced healthcare infrastructure and heightened awareness. Asia-Pacific is projected to experience notable growth, driven by increasing patient populations and improving access to treatment options.

Key players include Novartis, Pfizer, Merck, Eli Lilly, Bristol-Myers Squibb, Celgene, UCB, Amgen, Johnson & Johnson, GSK, AbbVie, and Sanofi. Strategies focus on developing innovative biologic therapies, expanding product portfolios, and forming strategic partnerships.

Read more: Global Psoriatic Arthritis Treatment Market Research Report

People Also Ask

Q1. What treatments are available for psoriatic arthritis?
Psoriatic arthritis treatments include nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs, biologics, and targeted synthetic DMARDs, offering specific therapeutic benefits for different patient needs and disease severity levels.

Q2. Which region leads the psoriatic arthritis treatment market?
North America leads due to high healthcare expenditure and prevalence of psoriatic arthritis, while Asia-Pacific is emerging rapidly, driven by increasing patient populations and improving access to treatment options.

Tags: psoriatic arthritis treatment, biologics, chronic inflammatory joint disease, nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, pharmaceutical

Site içinde arama yapın
Kategoriler
Read More
Party
Multiple Sclerosis Market: Competitive Developments in Neurological Therapeutics
Polaris Market Research has published its latest research report titled Multiple Sclerosis Market...
By pritijain1999 2026-11-05 12:31:09 0 200
Other
Ready-to-Eat Meat Products Market to Reach USD 55.46 Billion by 2033 Driven by Convenience Food Demand
The global Ready-to-Eat Meat Products Market is experiencing steady growth as consumers...
By ashlesha 2026-05-06 10:55:39 0 836
Other
Polyester Hot Melt Adhesives Market to Reach USD 1.78 Billion by 2036, India Leads at 14.2% CAGR
The global polyester hot melt adhesives market is projected to increase from USD 620 million in...
By Alexa 2026-10-10 03:30:48 0 355
Art
Global Antibiotics Market Set for Steady Growth, Valued at USD 56.90 Billion in 2025
In an increasingly competitive and evolving business landscape, making informed decisions backed...
By PolarisNews01 2026-09-03 11:54:11 0 472
Food
Nut Butters Market to Reach USD 8.8 Billion by 2036
The global Nut Butters Market is projected to grow from USD 4.5 billion in 2025 to USD 4.8...
By Satya12 2026-10-19 09:41:28 0 306